Levonorgestrel-releasing intrauterine system (Mirena®) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: A randomised controlled trial

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 50, Issue 3, 2010, Pages 273-279

  Wong, Alice Yuen Kwan ^a   Tang, Lawrence Chang Hung ^a   Chin, Robert Kien Howe ^a  

^a KWONG WAH HOSPITAL   (Hong Kong)

Author keywords

Bone mineral density; Depot medroxyprogesterone acetate; Endometriosis; Levonorgestrel releasing intrauterine system; Recurrence

Indexed keywords

LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT;

ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; ENDOMETRIOSIS; FEMALE; HUMAN; OBSTETRIC OPERATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ADULT; COMPARATIVE STUDY;

ADULT; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIOSIS; FEMALE; HUMANS; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE;

EID: 77953833819     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2010.01152.x     Document Type: Article

References (28)

1. Moore J, Kennedy SH, Prentice A. Modern combined oral contraception for pain associated with endometriosis. Cochrane Database Syst Rev 2000 2 CD001019.
2. Prentice A, Deary AJ, Goldbeck WS, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2000 2 CD000346.
3. Prentice A, Deary AJ, Bland C. Progestogens and antiprogestogens for pain associated with endometriosis. Cochrane Database Syst Rev 2000 2 CD002122.
4. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2001 4 CD000068.
5. Crosignani PG, Luciano A, Ray A, Bregqvist A. Subcutaneous depot medroxyprogesterone acetate Vs leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006 21 : 248 256. (Pubitemid 41794318)
6. Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006 85 (2 314 325. (Pubitemid 43170902)
7. Telimaa S, Puolakka J, Ronnberg L, Kaupilla A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987 1 : 13 23.
8. Shaarawy M, El-Mallah SY, Seoudi S, Hassan M, Mohsen IA. Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contracept 2006 74 (4 297 302.
9. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women age 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contracept 2006 74 (2 90 99.
10. Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesterone acetate. Contracept 2006 73 (6 577 583.
11. Vercellini P, Aimi G, Panazza S, De Giorgi O, Pesole A, Crosignani PG. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhoea associated with endometriosis: a pilot study. Fertil Steril 1999 72 : 505 508.
12. Vercellini P, Fontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003 80 (2 305 309.
13. Petta CA, Ferriani RA, Abrao MS et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005 20 (7 1993 1998.
14. Wichmann BA, Hill ID. Algorithm AS 183. An efficient and portable pseudo-random number generator. Appl Stat 1982 31 : 188 190.
15. Mcleod AI. Remark AS R58. A remark on algorithm AS 183. An efficient and portable pseudo-random number generator. Appl Stat 1985 34 : 198 200.
16. Vercellini P, Somigliana E, Vigano P, Abbiati A, Daguati R, Crosignani PG. Endometriosis: current and future medical therapies. Best Pract Res Clin Obstet Gynaecol 2008 22 (2 275 306.
17. Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Grosignani PG. Endometriosis: current therapies and new pharmacological developments. Drugs 2009 69 (6 649 675.
18. Osteen KG, Bruner-Tran KL, Ong D, Eisenberg E. Paracrine mediators of endometrial matrix metalloproteinases expression: potential targets for progestin-based treatment of endometriosis. Ann NY Acad Sci 2002 955 : 139 146.
19. Blei F, Wilson EL, Mignatti P, Rifkin DB. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993 155 : 568 578.
20. Schatz F, Lockwood CJ. Progestin regulation of plasminogen activator inhibitor type 1 in primary cultures of endometrial stromal and decidual cells. J Clin Endocrinol Metab 1993 77 : 621 625.
21. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004 82 (6 1580 1586.
22. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM. Depot medroxyprogesterone acetate and bone mineral density in adolescents - the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health 2006 39 (2 296 301.
23. Panay N. Advances in the medical management of endometriosis. BJOG 2008 115 (7 814 817.
24. Gomes MKO, Rosa-e-Silva JC, Garcia SB et al. Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium. Hum Reprod 2009 24 (11 2736 2745.
25. Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E. Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept 1995 11 : 85 95.
26. Nilsson CG, Lahteenmaki T, Robertson DN, Luukkainen T. Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intrauterine devices. Acta Endocrinol 1980 93 : 380 384.
27. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol 1982 17 : 529 536. (Pubitemid 12006959)
28. Bahamondes L, Espejo-Acre X, Hidalgo MM, Hidalgo-Regina C, Teatin-Juliato C, Petta CA. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Hum Reprod 2006 21 (5 1316 1319.